Invivyd Stock Today

IVVD Stock  USD 0.76  0.01  1.30%   

Performance

Insignificant

 
Weak
 
Strong

Odds Of Distress

Low

 
High
 
Low
Invivyd is trading at 0.76 as of the 23rd of July 2025, a 1.3% down since the beginning of the trading day. The stock's lowest day price was 0.75. Invivyd has about a 21 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 24th of April 2025 and ending today, the 23rd of July 2025. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
6th of August 2021
Category
Healthcare
Classification
Health Care
Invivyd, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. Invivyd, Inc. was incorporated in 2020 and is based in Waltham, Massachusetts. The company has 119.96 M outstanding shares of which 4.92 M shares are currently shorted by private and institutional investors with about 3.03 trading days to cover. More on Invivyd

Moving against Invivyd Stock

  0.34MRK Merck Company Earnings Call This WeekPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Invivyd Stock Highlights

VP CEOHeidi MS
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.160.18
Fairly Down
Slightly volatile
Gross Profit Margin0.750.84
Moderately Down
Slightly volatile
Total Current Liabilities46.7 M62 M
Way Down
Slightly volatile
Total Assets236.7 M129.5 M
Way Up
Slightly volatile
Total Current Assets95.6 M100.7 M
Notably Down
Slightly volatile
Debt Levels
Invivyd can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Invivyd's financial leverage. It provides some insight into what part of Invivyd's total assets is financed by creditors.
Liquidity
Invivyd currently holds 1.3 M in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Invivyd has a current ratio of 8.96, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Invivyd's use of debt, we should always consider it together with its cash and equity.

Investments

(147,000)
Invivyd (IVVD) is traded on NASDAQ Exchange in USA. It is located in 1601 Trapelo Road, Waltham, MA, United States, 02451 and employs 99 people. Invivyd is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 91.17 M. Invivyd conducts business under Biotechnology sector and is part of Health Care industry. The entity has 119.96 M outstanding shares of which 4.92 M shares are currently shorted by private and institutional investors with about 3.03 trading days to cover. Invivyd currently holds about 418.67 M in cash with (170.49 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.84, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Invivyd Probability Of Bankruptcy
Ownership Allocation
Invivyd has a total of 119.96 Million outstanding shares. Over half of Invivyd's outstanding shares are owned by outside corporations. These outside corporations are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Also note that almost eight million four hundred ninety-three thousand two hundred thirty-nine invesors are currently shorting Invivyd expressing very little confidence in its future performance.
Check Invivyd Ownership Details

Invivyd Stock Institutional Holders

InstituionRecorded OnShares
State Street Corp2025-03-31
997.1 K
Orbimed Advisors, Llc2025-03-31
933.5 K
Morgan Stanley - Brokerage Accounts2025-03-31
741.1 K
Deutsche Bank Ag2025-03-31
655.3 K
Northern Trust Corp2025-03-31
589 K
Duquesne Family Office Llc2025-03-31
571.4 K
Ubs Group Ag2025-03-31
440.7 K
Aqr Capital Management Llc2025-03-31
410.7 K
Tang Capital Management Llc2025-03-31
400 K
Mithril Ii Gp Lp2025-03-31
11.2 M
Maverick Capital Ltd2025-03-31
11 M
View Invivyd Diagnostics

Invivyd Historical Income Statement

At present, Invivyd's Research Development is projected to increase significantly based on the last few years of reporting. The current year's Total Operating Expenses is expected to grow to about 201.8 M, whereas Operating Income is forecasted to decline to (185.7 M). View More Fundamentals

Invivyd Stock Against Markets

Invivyd Corporate Management

Laura WalkerCoFounder OfficerProfile
Elham PharmDChief OfficerProfile
Peter MDChief OfficerProfile
Robert AllenChief OfficerProfile
Jill JDChief SecretaryProfile
Mark WingertzahnSenior AffairsProfile
Timothy LeeChief OfficerProfile
When determining whether Invivyd is a strong investment it is important to analyze Invivyd's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Invivyd's future performance. For an informed investment choice regarding Invivyd Stock, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Invivyd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
For information on how to trade Invivyd Stock refer to our How to Trade Invivyd Stock guide.
You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Invivyd. If investors know Invivyd will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Invivyd listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.19)
Revenue Per Share
0.307
Return On Assets
(0.58)
Return On Equity
(1.23)
The market value of Invivyd is measured differently than its book value, which is the value of Invivyd that is recorded on the company's balance sheet. Investors also form their own opinion of Invivyd's value that differs from its market value or its book value, called intrinsic value, which is Invivyd's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Invivyd's market value can be influenced by many factors that don't directly affect Invivyd's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Invivyd's value and its price as these two are different measures arrived at by different means. Investors typically determine if Invivyd is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Invivyd's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.